Italia markets close in 3 hours 51 minutes

Pyxis Oncology, Inc. (PYXS)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
3,7400-0,0700 (-1,84%)
Alla chiusura: 04:00PM EDT
3,5800 -0,16 (-4,28%)
Dopo ore: 07:40PM EDT
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023

    BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced four abstracts for four different assets have been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held November 1-5, 2023, in San Diego. “We look forward to presenting a trial-in-progress poster for PYX-201, our first-in-class a

  • GlobeNewswire

    Pyxis Oncology to Participate in Two Upcoming Investment Conferences

    BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced its participation in two upcoming investment conferences. On September 6, 2023, members of the Pyxis Oncology executive team will host in-person 1x1 meetings with investors during the 2023 Wells Fargo Healthcare Conference in Boston. To schedule a meeting, please reach out to your Wells Far

  • GlobeNewswire

    Pyxis Oncology Successfully Completes Acquisition of Apexigen

    Transaction adds a validated antibody-discovery platform, Phase 2 candidate and royalty stream Company positioned as a leader in next-generation, end-to-end Antibody-Drug Conjugate (“ADC”) creation with clinically and commercially validated platform capabilities Cash runway maintained into 1H 2025, enabling the Company to evaluate early signs of potential clinical activity for PYX-201 and PYX-106 Guidance on development strategy, timelines and milestones for the newly acquired Phase 2 sotigalima